Evidence map›Paper›PMID 40205370›Full record

ArticleBMC medical genomics2025

Putative function and prognostic molecular marker of mast cells in colorectal cancer.

Jiani Guo, Jie Chen, Yiting Wang, Xiaoming Bai, Haimei Feng, Siqi Sheng, Hongyu Wang, Ke Xu, Mengxi Huang, Zengjie Lei and 1 more

Abstract read
In one paragraph

Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiani Guo *Department of Medical Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China.
Jie Chen *Department of Medical Oncology, Affiliated Hospital of Medical School, Nanjing Jinling Hospital, Nanjing University, Nanjing, Jiangsu Province, China.
Yiting Wang *Department of Medical Oncology, Affiliated Hospital of Medical School, Nanjing Jinling Hospital, Nanjing University, Nanjing, Jiangsu Province, China.
Xiaoming BaiDepartment of Medical Oncology, Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, China.
Haimei FengDepartment of Medical Oncology, Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, China.
Siqi ShengDepartment of Medical Oncology, Affiliated Hospital of Medical School, Nanjing Jinling Hospital, Nanjing University, Nanjing, Jiangsu Province, China.
Hongyu WangDepartment of Medical Oncology, Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, China.
Ke XuDepartment of Medical Oncology, Affiliated Hospital of Medical School, Nanjing Jinling Hospital, Nanjing University, Nanjing, Jiangsu Province, China.
Mengxi HuangDepartment of Medical Oncology, Affiliated Hospital of Medical School, Nanjing Jinling Hospital, Nanjing University, Nanjing, Jiangsu Province, China. huangmengxi1@163.com.
Zengjie LeiDepartment of Medical Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China. leizengjie@163.com.
Xiaoyuan ChuDepartment of Medical Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China. chuxiaoyuan000@163.com.

Funding

China Postdoctoral Science Foundation 2020M670090ZXJiangsu Commission of Health ZD2021039National Natural Science Foundation of China 82072725
6 · The paper itself

Abstract

backgroundThe increased demand for markers for colorectal cancer (CRC) highlights the importance of investigating immune cells involved in CRC progression. This study aims to dissect the mast cells in CRC, characterize the role of mast cells in CRC development, coordinate molecular communication between mast cells and malignant cells, and construct and validate a prognostic classification model based on mast cell markers.

methodsSingle-cell transcriptome data of CRC patients were extracted from GSE146771 for cell classification and annotation. The malignant cells were identified by copykat and the communication between mast cells and malignant cells was analyzed by CellChat. Least absolute shrinkage and selection operator (LASSO) regression analysis and Cox regression analysis of mast cell markers were performed in the TCGA-COAD cohort to construct a prognostic classification model. qRT-PCR was performed to detect the mRNA expression of the molecules in the classification model in P815 and MC-9 cells. The co-culture experiment of MC38 and P815 cells were performed in 12-well transwell dish. Wound healing assay and Transwell assay were performed to detect cell migration and invasion.

results10,186 high-quality cells in GSE146771 were annotated to 9 cell types. Six markers in mast cells (HDC, GATA2, ASAH1, BTBD19, TIMP1, FAM110A) were selected to construct a classification model. The high-risk score defined showed high infiltration of immunosuppressive cells, including endothelial cells, CAFs, Tregs and high angiogenesis and epithelial-mesenchymal transition (EMT) activities. In the model, HDC were abnormally low expressed in P815 cells, while BTBD19, FAM110A, GATA2, ASAH1 and TIMP1 showed excessive expression in P815 cells. Knockdown of GATA2 in the co-culture system of P815 and MC38 cells blocked cell migration and invasion.

conclusionThis study identified the cell types within CRC, elaborated the cellular functions of mast cells in CRC development and their molecular communication to coordinate malignant cells, and highlighted the molecular components and biological features that constitute promising prognostic classification model.

Indexed as

Biomarkers, TumorColorectal NeoplasmsMast CellsCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, TumorCells co-cultureClassification modelColorectal cancerIntercellular communicationInvasionMast cellsMigrationPrognosisTumor microenvironment

Identifiers

PMID40205370
PMCPMC11983841

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.